- $5.10m
- -$4.98m
- $1.20m
U.S. STOCKS ON THE MOVE-Moderna, Addentax, Baxter
U.S. STOCKS ON THE MOVE-Chico's FAS, Nuwellis, Toyota
Longeveron up as heart disease therapy receives FDA's fast track tag
Brief: U.S. FDA Grants Fast Track Designation For Longeveron’s Lomecel-B
U.S. STOCKS ON THE MOVE-U.S.-listed China stocks, Big banks, Ford Motor
U.S. STOCKS ON THE MOVE-Longeveron, Plug Power, Tilray Brands
Longeveron rises on potential European patent related to cell therapy
Brief: Longeveron Receives Intent To Grant Notice From European Patent Office For Methods To Monitor Efficacy Of Lomecel-B Cell Therapy Through Levels Of Vascular Biomarker
Brief: Longeveron Inc. Reports Q2 2022 Financial Results
Brief: Longeveron Inc Reports Q1 Loss Per Share $0.17
Brief: Longeveron Announces CEO Transition
Brief: Longeveron Enters Into Agreement With US Dept Of Veterans Affairs For Its Phase 2 Alzheimer’s Trial
Brief: Longeveron Inc Files For Mixed Shelf Of Up To $50 Million – SEC Filing
Longeveron up on publication of early-stage trial results for Alzheimer's drug
Brief: Longeveron Publishes Peer Reviewed Study Of Phase 1 Trial Results Of Lomecel-B For Alzheimer's
Brief: Longeveron Says Dismissed Its Independent Registered Public Accounting Firm, Msl, P.A. Effective Immediately
Brief: Longeveron Reports Q4 Revenue Of $200,000
Brief: Longeveron Adds Seasoned Biotech Executive Todd Girolamo To Its Board Of Directors
Brief: Longeveron Announces Publication Of Lomecel-B Phase 2B Trial Design In Journal Of Frailty And Aging